Safety, immunogenicity, and efficacy of Ad5.F35-GUCY2C-PADRE vaccine in patients with GI cancers at high risk of relapse: Results from a phase 2A trial.

Authors

• Scott Waldman

Publication/Presentation Date

5-2026

Volume

44

Issue

16

Published In/Presented At

DOI: 10.1200/JCO.2026.44.16_suppl.3617

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article